131 related articles for article (PubMed ID: 11908677)
1. Hepatocyte growth factor expression in human cancer and therapy with specific inhibitors.
Haddad R; Lipson KE; Webb CP
Anticancer Res; 2001; 21(6B):4243-52. PubMed ID: 11908677
[TBL] [Abstract][Full Text] [Related]
2. Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis.
Zhang YW; Wang LM; Jove R; Vande Woude GF
Oncogene; 2002 Jan; 21(2):217-26. PubMed ID: 11803465
[TBL] [Abstract][Full Text] [Related]
3. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.
Li Y; Lal B; Kwon S; Fan X; Saldanha U; Reznik TE; Kuchner EB; Eberhart C; Laterra J; Abounader R
Cancer Res; 2005 Oct; 65(20):9355-62. PubMed ID: 16230398
[TBL] [Abstract][Full Text] [Related]
4. HGF/SF-met signaling in the control of branching morphogenesis and invasion.
Zhang YW; Vande Woude GF
J Cell Biochem; 2003 Feb; 88(2):408-17. PubMed ID: 12520544
[TBL] [Abstract][Full Text] [Related]
5. A novel recombinant soluble splice variant of Met is a potent antagonist of the hepatocyte growth factor/scatter factor-Met pathway.
Tiran Z; Oren A; Hermesh C; Rotman G; Levine Z; Amitai H; Handelsman T; Beiman M; Chen A; Landesman-Milo D; Dassa L; Peres Y; Koifman C; Glezer S; Vidal-Finkelstein R; Bahat K; Pergam T; Israel C; Horev J; Tsarfaty I; Ayalon-Soffer M
Clin Cancer Res; 2008 Jul; 14(14):4612-21. PubMed ID: 18628476
[TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis.
Sengupta S; Sellers LA; Cindrova T; Skepper J; Gherardi E; Sasisekharan R; Fan TP
Cancer Res; 2003 Dec; 63(23):8351-9. PubMed ID: 14678996
[TBL] [Abstract][Full Text] [Related]
7. Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer.
Toschi L; Jänne PA
Clin Cancer Res; 2008 Oct; 14(19):5941-6. PubMed ID: 18829470
[TBL] [Abstract][Full Text] [Related]
8. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
Christensen JG; Burrows J; Salgia R
Cancer Lett; 2005 Jul; 225(1):1-26. PubMed ID: 15922853
[TBL] [Abstract][Full Text] [Related]
9. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
Burgess T; Coxon A; Meyer S; Sun J; Rex K; Tsuruda T; Chen Q; Ho SY; Li L; Kaufman S; McDorman K; Cattley RC; Sun J; Elliott G; Zhang K; Feng X; Jia XC; Green L; Radinsky R; Kendall R
Cancer Res; 2006 Feb; 66(3):1721-9. PubMed ID: 16452232
[TBL] [Abstract][Full Text] [Related]
10. Hepatocyte growth factor stimulates cell motility in cultures of the striatal progenitor cells ST14A.
Cacci E; Salani M; Anastasi S; Perroteau I; Poiana G; Biagioni S; Augusti-Tocco G
J Neurosci Res; 2003 Dec; 74(5):760-8. PubMed ID: 14635227
[TBL] [Abstract][Full Text] [Related]
11. Hepatocyte growth factor/scatter factor, a cytokine playing multiple and converse roles.
Jiang WG; Hiscox S
Histol Histopathol; 1997 Apr; 12(2):537-55. PubMed ID: 9151142
[TBL] [Abstract][Full Text] [Related]
12. Hepatocyte growth factor/scatter factor induces feedback up-regulation of CD44v6 in melanoma cells through Egr-1.
Recio JA; Merlino G
Cancer Res; 2003 Apr; 63(7):1576-82. PubMed ID: 12670907
[TBL] [Abstract][Full Text] [Related]
13. Constitutive c-Met signaling through a nonautocrine mechanism promotes metastasis in a transgenic transplantation model.
Yu Y; Merlino G
Cancer Res; 2002 May; 62(10):2951-6. PubMed ID: 12019177
[TBL] [Abstract][Full Text] [Related]
14. Involvement of HGF/SF-Met signaling in prostate adenocarcinoma cells: evidence for alternative mechanisms leading to a metastatic phenotype in Pr-14c.
MacDougall CA; Vargas M; Soares CR; Holzer RG; Ide AE; Jorcyk CL
Prostate; 2005 Jul; 64(2):139-48. PubMed ID: 15678502
[TBL] [Abstract][Full Text] [Related]
15. Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4.
Matsumoto K; Nakamura T; Sakai K; Nakamura T
Proteomics; 2008 Aug; 8(16):3360-70. PubMed ID: 18646008
[TBL] [Abstract][Full Text] [Related]
16. Hepatocyte growth factor induces delayed STAT3 phosphorylation through interleukin-6 expression.
Lee BS; Park M; Cha HY; Lee JH
Cell Signal; 2009 Mar; 21(3):419-27. PubMed ID: 19071214
[TBL] [Abstract][Full Text] [Related]
17. In vivo molecular imaging of met tyrosine kinase growth factor receptor activity in normal organs and breast tumors.
Shaharabany M; Abramovitch R; Kushnir T; Tsarfaty G; Ravid-Megido M; Horev J; Ron R; Itzchak Y; Tsarfaty I
Cancer Res; 2001 Jun; 61(12):4873-8. PubMed ID: 11406565
[TBL] [Abstract][Full Text] [Related]
18. Coexpression of hepatocyte growth factor/scatter factor (HGF/SF) and its receptor cMET predict recurrence of meningiomas.
Martínez-Rumayor A; Arrieta O; Guevara P; Escobar E; Rembao D; Salina C; Sotelo J
Cancer Lett; 2004 Sep; 213(1):117-24. PubMed ID: 15312691
[TBL] [Abstract][Full Text] [Related]
19. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
Eder JP; Vande Woude GF; Boerner SA; LoRusso PM
Clin Cancer Res; 2009 Apr; 15(7):2207-14. PubMed ID: 19318488
[TBL] [Abstract][Full Text] [Related]
20. Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway.
Paumelle R; Tulasne D; Kherrouche Z; Plaza S; Leroy C; Reveneau S; Vandenbunder B; Fafeur V
Oncogene; 2002 Apr; 21(15):2309-19. PubMed ID: 11948414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]